Berotralstat and Ledipasvir: Interaction Details
- Berotralstat
- Orladeyo
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Berotralstat and Ledipasvir interaction:
Ledipasvir
We don't have a separate drug information page for Ledipasvir. The FDA's drug directory lists it as part of Harvoni (ledipasvir and sofosbuvir). Read the Ledipasvir and Sofosbuvir drug information page → Have a question about Ledipasvir? Ask a pharmacist, free →
What Happens When You Take Berotralstat With Ledipasvir
What can happen when they are taken together (rated Major)
Increased exposure
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
When given at twice the maximum recommended dose of 150 mg, berotralstat acts as a P-gp . Using berotralstat together with P-gp substrates may raise the exposure to those substrates, which can heighten the risk of the adverse reactions linked to them.
Dosages of berotralstat above the recommended level are not advised. The P-gp substrate should be monitored closely, or its dosage adjusted.1
The Berotralstat and Ledipasvir Interaction, Explained
Orladeyo (berotralstat) is taken to prevent hereditary angioedema attacks. Ledipasvir is a hepatitis C medicine, usually combined with sofosbuvir. Berotralstat can block , a pump that helps move ledipasvir out of your body's cells. When that pump is slowed, more ledipasvir can build up in your blood, which could raise the chance of side effects like headache or tiredness.
The listed concern is mainly tied to berotralstat doses higher than the recommended 150 mg. Please don't change anything on your own. Talk with your pharmacist or doctor, who can watch you closely and adjust your medicines if needed.
Mechanism: Berotralstat inhibits -mediated efflux (documented at supratherapeutic doses, 2 times the 150 mg maximum). Ledipasvir is a P-gp , so intestinal may rise and may fall, increasing exposure (/).
- Direction: increased ledipasvir exposure, with higher risk of ledipasvir-related adverse effects.
- Severity/evidence: major, probable; onset unspecified.
- Management: avoid berotralstat above the recommended dose; monitor closely for adverse reactions or modify the substrate dose as clinically appropriate.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Berotralstat and Ledipasvir Interact
The likely mechanism
of -mediated efflux transport by berotralstat
How to Manage the Berotralstat and Ledipasvir Interaction
Your care team can manage this. Typically they will make sure berotralstat is not taken above the recommended dose, since higher-than-recommended dosages are not advised. They may also monitor you more closely while you take both medicines, and the dose of the (here, ledipasvir) may need to be adjusted and individualized by your care team.
- Keep taking both medicines as prescribed unless told otherwise.
- Tell your pharmacist and prescriber about every medicine you take.
- Report new or worsening side effects, such as unusual tiredness or headache, promptly.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Berotralstat or Ledipasvir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: ORLADEYO oral capsules, oral pellets, berotralstat oral capsules, oral pellets
In a drug interaction study, giving berotralstat together with digoxin at a dose of 300 mg raised the by roughly 1.5 fold and the by roughly 1.5 fold.1
Berotralstat and Ledipasvir: Common Questions
How serious is the Berotralstat and Ledipasvir interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Berotralstat and Ledipasvir interaction managed?
Your care team can manage this. Typically they will make sure berotralstat is not taken above the recommended dose, since higher-than-recommended dosages are not advised. They may also monitor you more closely while you take both medicines, and the dose of the (here, ledipasvir) may need to be adjusted and individualized by your care team. Keep taking both medicines as prescribed un… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Ask About the Berotralstat and Ledipasvir Interaction
Ask in your own words about taking Berotralstat and Ledipasvir together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: ORLADEYO® oral capsules, oral pellets, berotralstat oral capsules, oral pellets. BioCryst Pharmaceuticals Inc (per manufacturer), Durham, NC, 2025. DailyMed
Other Serious Interactions of Berotralstat and Ledipasvir
Also serious with Berotralstat
- ColchicineContraindicated
- FlibanserinContraindicated
- LomitapideContraindicated
- Acetaminophen and CodeineMajor
Also serious with Ledipasvir
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven. This interaction.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.